Clinical trials: Kidney (Renal Cell) Cancer
Metastatic Renal Cell Carcinoma
Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients
This phase II open label trial randomized patients who completed the induction with nivolumab plus ipilimumab without complete response or progressive disease will be randomized 1:1 to receive axitinib in addition to nivolumab…
- Trial name
- AxIn (NCT05817903)
- Testing
- Axitinib, Nivolumab
- Where
- 23 sites in Italy
- Volunteers
- 118 people
- Sponsor
- Consorzio Oncotech
Clear Cell Renal Carcinoma
Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
The purpose of this trial is to determine if adjuvant therapy with axitinib will prevent or delay the recurrence of renal cell cancer after surgery to remove the primary tumor in high risk patients.
- Trial name
- ATLAS (NCT01599754)
- Testing
- Axitinib
- Where
- 106 sites in United States, China and 7 more
- Volunteers
- 724 people
- Sponsor
- SFJ Pharma Ltd. II
Brain and Central Nervous System Tumors, Kidney Cancer
Early Enteral Tube Feedings in Children Receiving Chemo for AML/MDS & High Risk Solid Tumors
RATIONALE: Tubefeeding may help maintain good nutrition and lessen weight loss in younger patients receiving chemotherapy for cancer.
- Conditions
- Brain and Central Nervous System Tumors, Kidney Cancer, Leukemia, Liver Cancer
- Trial name
- NCT00624962
- Testing
- nutritional intervention, therapeutic nutritional supplementation
- Sponsor
- Vanderbilt University
Renal Cell Carcinoma, Urothelial Carcinoma
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC)…
- Conditions
- Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer
- Trial name
- NCT06966024
- Testing
- DCC-2812
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Kidney Cancer
Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer
RATIONALE: A peripheral stem cell transplant or bone marrow transplant from a brother or sister may be an effective treatment for kidney cancer.
- Trial name
- NCT00262886
- Testing
- anti-thymocyte globulin, graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Rochester
Immune Checkpoint Inhibitors, Cytoreductive Nephrectomy
Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
Study Objective: To determine the efficacy of upfront immune checkpoint inhibitors combined with deferred cytoreductive nephrectomy in treating metastatic renal cell carcinoma.
- Conditions
- Immune Checkpoint Inhibitors, Cytoreductive Nephrectomy, Clear Cell Renal Cell Cancer (ccRCC)
- Trial name
- NCT06279403
- Testing
- Toripalimab, Cytoreductive Nephrectomy, Axitinib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- RenJi Hospital
Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab
The purpose of this study is to see if continued nivolumab with the addition of ipilimumab plus hypo-fractionated stereotactic radiation (sTR) of a single lesions results in partial or complete responses in patients with…
- Trial name
- NCT03149159
- Testing
- Nivolumab, Ipilimumab, Steriotactic radiation therapy
- Where
- United States
- Sponsor
- Medical University of South Carolina
Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic
Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
The purpose of this research study is to test the safety and effectiveness of Seleno-L Methionine (SLM) when combined with the standard dose and schedule of Axitinib and Pembrolizumab in patients who have locally advanced or…
- Trial name
- NCT05363631
- Testing
- Selenomethionine (SLM), Axitinib, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Fernando Maciel Barbosa
Pediatric Solid Tumor, Sarcoma
iCAT for Recurrent/Refractory/HR Solid Tumors
In this study tumor will be tested for cancer causing gene alterations such as mutations or copy number alterations. This is called tumor profiling.
- Conditions
- Pediatric Solid Tumor, Sarcoma, Neuroblastoma, Wilms Tumor
- Trial name
- NCT01853345
- Where
- 5 sites in United States
- Volunteers
- 101 people
- Sponsor
- Dana-Farber Cancer Institute
Bladder (Urothelial, Transitional Cell) Cancer, Kidney (Renal Cell) Cancer
Effectiveness of a Personalized 6-month Programme on Frailty in Older Patients Treated for Bladder or Kidney Cancer.
Bladder and kidney cancers are commonly diagnosed in older adults. Surgery remains the primary treatment modality for patients with kidney or bladder cancer.
- Trial name
- FRAGECO (NCT07073703)
- Testing
- APA, Therapeutic education workshops, DAPAP
- Where
- 2 sites in France
- Volunteers
- 106 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Sarcoma, Multiple Myeloma
Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence
Positron Emission Tomography (PET) is a specialised nuclear medicine procedure that uses positron emitting radiolabeled tracer molecules to measure biological activity.
- Conditions
- Sarcoma, Multiple Myeloma, Testicular Neoplasms, Ovarian Neoplasms
- Trial name
- NCT00123773
- Testing
- Positron Emission Tomography
- Where
- Canada
- Volunteers
- 1,075 people
- Sponsor
- AHS Cancer Control Alberta
Urological Malignancies, Prostate Cancer
Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome
Genitourinary malignancies such as prostate cancer, renal cell cancer, and bladder cancer in Korean population have been increased due to the aged population and the westernized lifestyles.
- Conditions
- Urological Malignancies, Prostate Cancer, Renal Cell Cancer, Bladder Cancer
- Trial name
- NCT04625556
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- Yonsei University
Kidney Neoplasms
Assessment of Oncological and Functional Outcomes After Robot Assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy
Currently, partial nephrectomy (PN) is considered as the gold standard treatment modality for small renal masses. In this setting, robot-assisted and conventional laparoscopic approaches are gaining more consensus every day.
- Trial name
- NCT02924922
- Testing
- Laparoscopic partial nephrectomy, Robot assisted partial nephrectomy, Conventional laparoscopic instruments
- Where
- Switzerland
- Volunteers
- 85 people
- Sponsor
- Luzerner Kantonsspital
Bladder Cancer, Kidney Cancer
Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Bladder Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00016237
- Testing
- tucotuzumab celmoleukin
- Where
- 2 sites in United States
- Sponsor
- EMD Serono
Solid Tumor, Clear Cell Renal Cell Carcinoma
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
This is a first-in-human open-label Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-00610 given by intravenous infusion in patients with…
- Conditions
- Solid Tumor, Clear Cell Renal Cell Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- NCT05199272
- Testing
- 23ME-00610
- Where
- 13 sites in United States, Canada
- Volunteers
- 141 people
- Sponsor
- 23andMe, Inc.
Covid19
Comorbidities and Risk Score in COVID-19 Patients
Retrospective multi-center cohort study. Consecutive patients hospitalized for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) up to October 2020 will be included.
- Trial name
- Comorbidities (NCT04670094)
- Where
- 5 sites in Italy
- Volunteers
- 4,555 people
- Sponsor
- University of Milano Bicocca
Multiple Myeloma, Light Chain Nephropathy
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
Objective 1: To test whether treatment with plasma exchange improves renal recovery in patients with light chain cast nephropathy Objective 2: To compare renal outcomes among patients treated with plasma exchange versus…
- Conditions
- Multiple Myeloma, Light Chain Nephropathy, Acute Kidney Injury
- Trial name
- NCT06483139
- Testing
- Plasma exchange, Daratumumab
- Where
- United States
- Volunteers
- 549 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma
A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors
The aim of the Phase Ia portion is to identify the maximum tolerated dose or maximum acceptable dose MTD/MAD of HS-10516. The phase Ib portion will evaluate the preliminary efficacy of HS-10516 in patients with VHL Syndrome…
- Trial name
- NCT06553339
- Testing
- Oral HS-10516
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Bladder Cancer, Renal Cancer
Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells
Treatment of metastatic tumors of the urogenital area with cytokine-induced killer cells
- Trial name
- NCT05108077
- Testing
- cytokine-induced killer cells, Standard treatment according to the Clinical protocols
- Where
- Belarus
- Volunteers
- 20 people
- Sponsor
- Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.